Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLASTAR observational study of polatuzumab vedotin plus R-CHP in untreated diffuse large B-cell lymphoma
jRCT1071220082Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin and prednisone in diffuse large B-cell lymphoma (DLBCL), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Feb 2023; status: active, not recruiting.
02
Drugs
polatuzumab vedotinrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT1071220082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071220082.